Brokerages Expect Unum Therapeutics Inc (NASDAQ:UMRX) Will Post Quarterly Sales of $3.11 Million

Share on StockTwits

Analysts predict that Unum Therapeutics Inc (NASDAQ:UMRX) will announce $3.11 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Unum Therapeutics’ earnings. The lowest sales estimate is $1.80 million and the highest is $4.41 million. Unum Therapeutics reported sales of $2.04 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 52.5%. The firm is scheduled to report its next quarterly earnings results on Monday, November 11th.

According to Zacks, analysts expect that Unum Therapeutics will report full year sales of $13.85 million for the current year, with estimates ranging from $9.70 million to $17.60 million. For the next year, analysts forecast that the company will post sales of $16.91 million, with estimates ranging from $9.00 million to $25.33 million. Zacks’ sales calculations are an average based on a survey of research analysts that follow Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Unum Therapeutics had a negative net margin of 340.49% and a negative return on equity of 75.60%. The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.10 million.

Several research firms have recently commented on UMRX. SunTrust Banks reduced their price target on shares of Unum Therapeutics to $6.00 and set a “buy” rating for the company in a research report on Wednesday, July 3rd. Cowen reaffirmed a “hold” rating on shares of Unum Therapeutics in a research report on Monday, August 12th. Zacks Investment Research raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Friday, April 26th. HC Wainwright reaffirmed a “buy” rating on shares of Unum Therapeutics in a research report on Tuesday. Finally, ValuEngine raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.40.

A number of institutional investors have recently added to or reduced their stakes in UMRX. BlackRock Inc. lifted its position in Unum Therapeutics by 281.5% during the fourth quarter. BlackRock Inc. now owns 1,530,419 shares of the company’s stock valued at $6,733,000 after purchasing an additional 1,129,262 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Unum Therapeutics by 251.5% during the fourth quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after purchasing an additional 33,091 shares during the last quarter. Northern Trust Corp lifted its position in Unum Therapeutics by 312.6% during the fourth quarter. Northern Trust Corp now owns 178,640 shares of the company’s stock valued at $786,000 after purchasing an additional 135,345 shares during the last quarter. Geode Capital Management LLC lifted its position in Unum Therapeutics by 85.4% during the fourth quarter. Geode Capital Management LLC now owns 132,565 shares of the company’s stock valued at $583,000 after purchasing an additional 61,061 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Unum Therapeutics by 11.6% during the fourth quarter. Bank of America Corp DE now owns 99,545 shares of the company’s stock valued at $438,000 after purchasing an additional 10,317 shares during the last quarter. 47.16% of the stock is owned by institutional investors.

Shares of NASDAQ UMRX traded up $0.25 during midday trading on Friday, hitting $2.00. 32,000 shares of the company’s stock traded hands, compared to its average volume of 131,761. Unum Therapeutics has a 1 year low of $1.50 and a 1 year high of $16.72. The stock has a market capitalization of $55.50 million, a price-to-earnings ratio of -1.44 and a beta of 1.38. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.65 and a current ratio of 2.41. The firm has a fifty day moving average of $2.22 and a 200 day moving average of $3.34.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Read More: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.